Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
The latest announcement is out from Takeda Pharmaceutical Co ( (JP:4502) ).
Takeda Pharmaceutical Co announced new assignments of directors following its 149th Annual Meeting of Shareholders. The board, comprised predominantly of external directors, underscores Takeda’s commitment to strong, independent governance. This governance model is crucial for aligning decisions with stakeholder interests and maintaining the company’s values. The new assignments include roles in the Nomination and Compensation Committees, further emphasizing the company’s focus on transparency and objectivity in its operations.
The most recent analyst rating on (JP:4502) stock is a Hold with a Yen4200.00 price target. To see the full list of analyst forecasts on Takeda Pharmaceutical Co stock, see the JP:4502 Stock Forecast page.
More about Takeda Pharmaceutical Co
Takeda Pharmaceutical Co is a leading values-based, R&D-driven biopharmaceutical company headquartered in Japan. The company focuses on creating better health outcomes through life-transforming treatments in core areas such as gastrointestinal and inflammation, rare diseases, plasma-derived therapies, oncology, neuroscience, and vaccines. With operations in approximately 80 countries, Takeda is committed to improving patient experiences and advancing treatment options.
Average Trading Volume: 4,923,874
Technical Sentiment Signal: Strong Buy
Current Market Cap: Yen6789.9B
See more insights into 4502 stock on TipRanks’ Stock Analysis page.